For U.S. Healthcare Professionals Only

MAKE A REQUEST

Request a Sales Professional
Request a Reprint
Request Samples

ADDITIONAL INFORMATION

Request an MSL
Eisai Reimbursement
Eisai Medical Information

OUR PRODUCTS

DAYVIGO^® (lemborexant) CIV
LENVIMA^® (lenvatinib)
HALAVEN^® (eribulin mesylate)

Home
/
Request Samples
/

MAKE A REQUEST

Request a reprint, a sample, or a meeting with a sales professional anytime.

Request a Sales Professional
Request a Reprint
Request Samples

REQUEST SAMPLES

Start the sample request process by
choosing an
Eisai product. You will be taken
to its Sample Portal.

DAYVIGO® Healthcare Professionals website

DAYVIGO® Healthcare Professionals website

Eisai Corporate
Eisai Reimbursement
Medical Information
Contact Us
Privacy Policy
Terms of Use

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a health care provider. All decisions regarding patient care must be made with a health care professional, considering the unique characteristics of the patient. This site is intended for U.S. health care providers only. The products discussed herein may have different product labeling in different countries. To report suspected adverse reactions, contact Eisai Inc. at 1-888-274-23781-888-274-2378 or the FDA at 1-800-FDA-10881-800-FDA-1088 or www.FDA.gov/medwatch.

YOU ARE ABOUT TO LEAVE THE
EISAI ENGAGE WEBSITE

Eisai does not review the information contained on the following Website for content, accuracy, or completeness. Use of and access to the information is subject to the terms, limitations, and conditions set by the Website producer. Eisai makes no claims about the accuracy or any other aspect of the information contained on the Website, nor does Eisai endorse the Website. Click CONTINUE if you agree. Want to stay on our site? Simply click CANCEL.

PLEASE CONFIRM YOU ARE AN HCP AND YOU ARE
LOOKING FOR AN MSL FOR ONE OF THE PRODUCTS
LISTED BELOW.

Copyright ©2021 Eisai Inc. All Rights Reserved.
CORP-US3024 September 2021

Intended for residents of the United States only.